Dormer Stephen is Co-Chair of the Firm's Business and Finance Practice Group.
Dormer handles venture capital and private equity and debt transactions, mergers and acquisitions and general corporate matters. His practice involves the representation of Fortune 500 companies, private equity funds, emerging growth companies and investment banks in structuring, negotiating and documenting seed through later stage equity and debt investments, mezzanine financings, syndicated credit facilities, mergers and acquisitions, buyouts, rollup strategies, joint ventures, intellectual property transactions, work-outs and financial restructurings and general corporate matters. Constituent companies are in a broad range of industries including financial services, insurance, life sciences, media, software and telecommunications. He also represents public and private clients in an “outside general counsel” capacity. Roles include counseling on strategic initiatives (such as joint ventures, joint development projects and intellectual property licensing and collaboration), commercial contract matters (such as distribution and supply agreements, license agreements and employment agreements) and other general corporate matters (such as employment and severance matters, equity incentive plans, corporate governance, real estate matters and insurance matters).
Prior to joining Shipman & Goodwin, Dormer was a Partner in the Corporate Department of Dewey & LeBoeuf LLP.
Shipman & Goodwin represented Arvinas, a private biotechnology company creating a new class of drugs based on targeted protein degradation, in connection with its Series B financing round of $41.6 million. All of the initial Series A investors, including the two lead Series A investors, Canaan Partners and 5AM Ventures, participated in this new round. Three additional leading venture firms joined the round: RA Capital Management, OrbiMed, and New Leaf Venture Partners. Over the past month, Arvinas has been recognized as a Fierce 15 company, signed up Genentech as its second marquee collaborator and now has garnered this $41.6 million Series B round to continue its pipeline development work.
Arvinas is harnessing the body’s own natural degradation and removal system to target and degrade pathogenic proteins by using bifunctional small molecules, Proteolysis-Targeting Chimeras (PROTACs). See more at: http://www.fiercebiotech.com/story/arvinas-scores-41m-round-landmark-month/2015-10-21
Represented HighCape Partners in connection with the formation and financing of Aziyo Biologics, Inc., a regenerative medicine company, and the acquisition of Tissue Banks International’s musculoskeletal tissue division. Aziyo develops and delivers customized tissue products for use in orthopedic, spinal, sports medicine and dermal applications.
View All »
Your e-mail and any information in your e-mail to this individual are
not protected by the attorney client privilege. Therefore your e-mail
should not contain any confidential information and should be for
general information purposes only. The e-mail to this individual is not
intended to create, and does not constitute, an attorney-client